Profile data is unavailable for this security.
About the company
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
- Revenue in USD (TTM)5.90m
- Net income in USD-126.61m
- Incorporated2016
- Employees174.00
- LocationGeneration Bio Co301 BINNEY STREETCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 529-5908
- Fax+1 (302) 655-5049
- Websitehttps://generationbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 213.99m | 147.00 | -- | -- | -- | 1.83 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Galectin Therapeutics Inc | 0.00 | -44.81m | 214.81m | 14.00 | -- | -- | -- | -- | -0.7456 | -0.7456 | 0.00 | -0.9739 | 0.00 | -- | -- | 0.00 | -165.97 | -92.08 | -394.92 | -121.97 | -- | -- | -- | -- | -- | -12.72 | 6.24 | -- | -- | -- | -15.26 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -30.09m | 215.52m | 10.00 | -- | 2.37 | -- | -- | -0.2386 | -0.2386 | 0.00 | 0.7264 | 0.00 | -- | -- | 0.00 | -27.39 | -29.97 | -28.80 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 217.98m | -- | -- | 11.48 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -49.43m | 218.17m | 72.00 | -- | -- | -- | -- | -2.22 | -2.22 | 0.00 | 5.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 221.27m | 121.00 | -- | 1.30 | -- | 61.46 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| INmune Bio Inc | 155.00k | -30.01m | 221.32m | 11.00 | -- | 5.27 | -- | 1,427.89 | -1.67 | -1.67 | 0.0086 | 2.12 | 0.0022 | -- | 0.0284 | 14,090.91 | -43.24 | -37.82 | -54.85 | -41.86 | -- | -- | -19,360.00 | -14,901.03 | -- | -13.06 | 0.2064 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Generation Bio Co | 5.90m | -126.61m | 222.74m | 174.00 | -- | 1.09 | -- | 37.73 | -1.97 | -1.97 | 0.0916 | 3.07 | 0.0157 | -- | 2.71 | 33,931.04 | -33.72 | -36.96 | -36.60 | -39.21 | -- | -- | -2,144.51 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Puma Biotechnology Inc | 226.63m | 15.38m | 222.86m | 185.00 | 14.35 | 4.37 | 8.28 | 0.9834 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 223.24m | 100.00 | -- | 8.04 | -- | 2.66 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Zevra Therapeutics Inc | 27.46m | -46.05m | 223.86m | 65.00 | -- | 3.46 | -- | 8.15 | -1.29 | -1.29 | 0.7746 | 1.49 | 0.1909 | -- | 2.14 | 422,476.90 | -32.02 | -32.11 | -45.61 | -39.89 | 45.22 | -- | -167.69 | -128.42 | -- | -- | 0.4058 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 227.40m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P3 Health Partners Inc | 1.27bn | -57.77m | 229.00m | 400.00 | -- | 0.5946 | -- | 0.1808 | -0.6494 | -0.6494 | 13.37 | 1.22 | 1.46 | -- | 13.23 | 3,165,938.00 | -21.46 | -- | -96.06 | -- | 2.50 | 0.1781 | -14.72 | -56.93 | -- | -10.33 | 0.1999 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| AVITA Medical Inc | 50.14m | -35.38m | 229.62m | 207.00 | -- | 4.66 | -- | 4.58 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.33 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Data as of May 06 2024. Currency figures normalised to Generation Bio Co's reporting currency: US Dollar USD
45.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 6.87m | 10.33% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.35m | 8.05% |
| Bellevue Asset Management AGas of 31 Dec 2023 | 3.62m | 5.44% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.90m | 4.36% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 2.81m | 4.23% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.51m | 3.77% |
| EcoR1 Capital, LLCas of 31 Dec 2023 | 2.05m | 3.08% |
| PFM Health Sciences LPas of 31 Dec 2023 | 1.62m | 2.44% |
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 1.26m | 1.90% |
| BofA Securities, Inc.as of 31 Dec 2023 | 1.26m | 1.90% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
